{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:37:41Z","timestamp":1793504261711,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s40265-021-01606-x","type":"journal-article","created":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T22:20:15Z","timestamp":1633645215000},"page":"1921-1927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Belzutifan: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Emma D.","family":"Deeks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"issue":"24","key":"1606_CR1","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1093\/ajhp\/zxaa308","volume":"77","author":"C Chung","year":"2020","unstructured":"Chung C. From oxygen sensing to angiogenesis: targeting the hypoxia signaling pathway in metastatic kidney cancer. Am J Health Syst Pharm. 2020;77(24):2064\u201373.","journal-title":"Am J Health Syst Pharm"},{"issue":"12","key":"1606_CR2","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1016\/j.drudis.2019.09.008","volume":"24","author":"Y Yu","year":"2019","unstructured":"Yu Y, Yu Q, Zhang X. Allosteric inhibition of HIF-2\u03b1 as a novel therapy for clear cell renal cell carcinoma. Drug Discov Today. 2019;24(12):2332\u201340.","journal-title":"Drug Discov Today"},{"issue":"1","key":"1606_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cancers13010159","volume":"13","author":"T Schonberger","year":"2021","unstructured":"Schonberger T, Fandrey J, Prost-Fingerle K. Ways into understanding HIF inhibition. Cancers. 2021;13(1):1\u201316.","journal-title":"Cancers"},{"key":"1606_CR4","unstructured":"Merck Sharp & Dohme Corp. Welireg\u2122 (belzutifan) tablets, for oral use: US prescribing information. 2021. https:\/\/www.accessdata.fda.gov\/. Accessed 24 Aug 2021."},{"key":"1606_CR5","unstructured":"National Organization for Rare Disorders. Von Hippel-Lindau disease. 2021. https:\/\/rarediseases.org\/rare-diseases\/von-hippel-lindau-disease\/. Accessed 24 Aug 2021."},{"issue":"6","key":"1606_CR6","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/ejhg.2010.175","volume":"19","author":"ER Maher","year":"2011","unstructured":"Maher ER, Neumann HP, Richard S. von Hippel-Lindau disease: a clinical and scientific review. Eur J Hum Genet. 2011;19(6):617\u201323.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"1606_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1038\/s41571-019-0209-1","volume":"16","author":"RR Kotecha","year":"2019","unstructured":"Kotecha RR, Motzer RJ, Voss MH. Towards individualized therapy for metastatic renal cell carcinoma. Nat Rev Clin Oncol. 2019;16(10):621\u201333.","journal-title":"Nat Rev Clin Oncol"},{"issue":"15","key":"1606_CR8","doi-asserted-by":"publisher","first-page":"4726","DOI":"10.1158\/1078-0432.CCR-07-4921","volume":"14","author":"ML Nickerson","year":"2008","unstructured":"Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008;14(15):4726\u201334.","journal-title":"Clin Cancer Res"},{"key":"1606_CR9","unstructured":"Merck & Co. FDA approves Merck\u2019s hypoxia-inducible factor-2 alpha (HIF-2\u03b1) inhibitor Welireg\u2122 (belzutifan) for the treatment of patients with certain types of von Hippel-Lindau (VHL) disease-associated tumors [media release]. 13 Aug 2021. https:\/\/www.merck.com."},{"key":"1606_CR10","unstructured":"Merck AG. Merck to acquire Peloton Therapeutics, bolstering oncology pipeline [media release]. 22 May 2019. http:\/\/www.merck.com."},{"key":"1606_CR11","unstructured":"Merck C. Merck announces second-quarter 2019 financial results [media release]. 31 Jul 2019. http:\/\/www.merck.com."},{"key":"1606_CR12","unstructured":"Merck & Co Inc. Form 10-K. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/310158\/000031015821000004\/mrk-20201231.htm. Accessed 24 Aug 2021."},{"issue":"15","key":"1606_CR13","doi-asserted-by":"publisher","first-page":"6876","DOI":"10.1021\/acs.jmedchem.9b00719","volume":"62","author":"R Xu","year":"2019","unstructured":"Xu R, Wang K, Rizzi JP, et al. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a hypoxia-inducible factor 2\u03b1 (HIF-2\u03b1) inhibitor for the treatment of clear cell renal cell carcinoma. J Med Chem. 2019;62(15):6876\u201393.","journal-title":"J Med Chem"},{"issue":"18","key":"1606_CR14","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1182\/blood.2020009138","volume":"137","author":"MC Ghosh","year":"2021","unstructured":"Ghosh MC, Zhang DL, Ollivierre WH, et al. Therapeutic inhibition of HIF-2\u03b1 reverses polycythemia and pulmonary hypertension in murine models of human diseases. Blood. 2021;137(18):2509\u201319.","journal-title":"Blood"},{"key":"1606_CR15","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.3389\/fphys.2019.01534","volume":"10","author":"S Suresh","year":"2019","unstructured":"Suresh S, Rajvanshi PK, Noguchi CT. The many facets of erythropoietin physiologic and metabolic response. Front Physiol. 2019;10:1534.","journal-title":"Front Physiol"},{"issue":"5","key":"1606_CR16","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1038\/s41591-021-01324-7","volume":"27","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, Papadopoulos KP, et al. Inhibition of hypoxia-inducible factor-2\u03b1 in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis. Nat Med. 2021;27(5):802\u20135.","journal-title":"Nat Med"},{"issue":"15 Suppl","key":"1606_CR17","doi-asserted-by":"publisher","first-page":"4555","DOI":"10.1200\/JCO.2021.39.15_suppl.4555","volume":"39","author":"R Srinivasan","year":"2021","unstructured":"Srinivasan R, Donskov F, Iliopoulos O, et al. Phase 2 study of belzutifan (MK6482), an oral hypoxia-inducible factor 2alpha (HIF-2alpha) inhibitor, for von Hippel-Lindau (VHL) disease associated clear cell renal cell carcinoma (ccRCC) [abstract no. 4555]. J Clin Oncol. 2021;39(15 Suppl):4555.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1606_CR18","first-page":"32","volume":"62","author":"H Wiley","year":"2021","unstructured":"Wiley H, Coleman HR, Jonasch E, et al. Oral HIF-2\u03b1 inhibitor belzutifan for ocular von Hippel-Lindau (VHL) disease. Investig Ophthalmol Visual Sci Conf. 2021;62(8):32.","journal-title":"Investig Ophthalmol Visual Sci Conf."},{"issue":"6 Suppl","key":"1606_CR19","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1200\/JCO.2021.39.6_suppl.272","volume":"39","author":"TK Choueiri","year":"2021","unstructured":"Choueiri TK, Bauer TM, McDermott DF, et al. Phase 2 study of the oral hypoxiainducible factor 2alpha (HIF-2alpha) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC) [abstract no. 272]. J Clin Oncol. 2021;39(6 Suppl):272.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01606-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01606-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T01:14:22Z","timestamp":1636506862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01606-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":19,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["1606"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01606-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"6 October 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Emma Deeks is a contracted employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}